This months article is an intersting review that summarizes the current understanding of potential cardiovascular toxicities of CD19-specific Car T cell therapies.
CD19-specific chimeric antigen receptor (CAR) T cell therapies have shown remarkable early success in highly refractory and relapsing hematological malignancies. However, most significant side effects of the therapy are cytokine release syndrome (CRS) and neurotoxicity, but also cardiovascular toxicities like QT-prolongation, arrhythmias and hypotension.
The question here: Is CAR T cell–associated cardiotoxicity a systemic disease related to CRS or is it a direct cardiotoxic effect of Car T cells?
Find the article here: https://www.jacc.org/doi/full/10.1016/j.jaccao.2020.02.011
